364 related articles for article (PubMed ID: 29184673)
21. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
Appierto V; Di Cosimo S; Reduzzi C; Pala V; Cappelletti V; Daidone MG
Semin Cancer Biol; 2017 Jun; 44():106-116. PubMed ID: 28442298
[TBL] [Abstract][Full Text] [Related]
22. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.
Bracht JWP; Mayo-de-Las-Casas C; Berenguer J; Karachaliou N; Rosell R
Curr Oncol Rep; 2018 Jul; 20(9):70. PubMed ID: 30030656
[TBL] [Abstract][Full Text] [Related]
23. Circulating DNA in
Singh AP; Li S; Cheng H
Ann Transl Med; 2017 Sep; 5(18):379. PubMed ID: 29057239
[TBL] [Abstract][Full Text] [Related]
24. Detection and application of circulating tumor cell and circulating tumor DNA in the non-small cell lung cancer.
Zhang Y; Zheng H; Zhan Y; Long M; Liu S; Lu J; Zang H; Fan S
Am J Cancer Res; 2018; 8(12):2377-2386. PubMed ID: 30662798
[TBL] [Abstract][Full Text] [Related]
25. Current status and future perspectives of liquid biopsy in non-small cell lung cancer.
Chang S; Hur JY; Choi YL; Lee CH; Kim WS
J Pathol Transl Med; 2020 May; 54(3):204-212. PubMed ID: 32460474
[TBL] [Abstract][Full Text] [Related]
26. The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments.
Di Capua D; Bracken-Clarke D; Ronan K; Baird AM; Finn S
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439082
[TBL] [Abstract][Full Text] [Related]
27. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
Rolfo C; Mack PC; Scagliotti GV; Baas P; Barlesi F; Bivona TG; Herbst RS; Mok TS; Peled N; Pirker R; Raez LE; Reck M; Riess JW; Sequist LV; Shepherd FA; Sholl LM; Tan DSW; Wakelee HA; Wistuba II; Wynes MW; Carbone DP; Hirsch FR; Gandara DR
J Thorac Oncol; 2018 Sep; 13(9):1248-1268. PubMed ID: 29885479
[TBL] [Abstract][Full Text] [Related]
28. New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.
Duréndez-Sáez E; Azkárate A; Meri M; Calabuig-Fariñas S; Aguilar-Gallardo C; Blasco A; Jantus-Lewintre E; Camps C
J Thorac Dis; 2017 Oct; 9(Suppl 13):S1332-S1345. PubMed ID: 29184672
[TBL] [Abstract][Full Text] [Related]
29. Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in
Dietz S; Christopoulos P; Gu L; Volckmar AL; Endris V; Yuan Z; Ogrodnik SJ; Zemojtel T; Heussel CP; Schneider MA; Meister M; Muley T; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31753813
[TBL] [Abstract][Full Text] [Related]
30. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
[TBL] [Abstract][Full Text] [Related]
32. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
33. The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor.
Chen Y; Guo W; Fan J; Chen Y; Zhang X; Chen X; Luo P
Cancer Manag Res; 2017; 9():801-811. PubMed ID: 29263703
[TBL] [Abstract][Full Text] [Related]
34. Blood-based tumor biomarkers in lung cancer for detection and treatment.
Mamdani H; Ahmed S; Armstrong S; Mok T; Jalal SI
Transl Lung Cancer Res; 2017 Dec; 6(6):648-660. PubMed ID: 29218268
[TBL] [Abstract][Full Text] [Related]
35. The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer.
Bożyk A; Nicoś M
Life (Basel); 2022 Oct; 12(10):. PubMed ID: 36295075
[TBL] [Abstract][Full Text] [Related]
36. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?
Ilie M; Hofman V; Long E; Bordone O; Selva E; Washetine K; Marquette CH; Hofman P
Ann Transl Med; 2014 Nov; 2(11):107. PubMed ID: 25489581
[TBL] [Abstract][Full Text] [Related]
37. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
38. Blood-based biomarkers in lung cancer: prognosis and treatment decisions.
Xu-Welliver M; Carbone DP
Transl Lung Cancer Res; 2017 Dec; 6(6):708-712. PubMed ID: 29218272
[TBL] [Abstract][Full Text] [Related]
39. Liquid biopsy and NSCLC.
Trombetta D; Sparaneo A; Fabrizio FP; Muscarella LA
Lung Cancer Manag; 2016 Jun; 5(2):91-104. PubMed ID: 30643553
[TBL] [Abstract][Full Text] [Related]
40. Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients.
Provencio M; Pérez-Callejo D; Torrente M; Martin P; Calvo V; Gutiérrez L; Franco F; Coronado MJ; Cruz-Bermúdez JL; Ruiz-Valdepeñas AM; Cruz-Bermúdez A; Sánchez-Beato M; Romero A; García-Grande A
Oncotarget; 2017 Aug; 8(35):59408-59416. PubMed ID: 28938646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
